Elevate Farms Inc., Tech-based Vertical Farming, Announces Results of Annual General and Special Meeting

Sep 20, 2022

TORONTO, - Elevate Farms Inc. ("Elevate" or "Elevate Farms"), a tech-based vertical farming company focused on cost-effectively ‎‎growing leafy green vegetables at mass scale, is pleased to announce the results of its annual general and special meeting of shareholders ("Shareholders") held on Friday, September 16, 2022 ("Meeting").

At the Meeting, Shareholders re-appointed the three existing directors of the Corporation, being Amin Jadavji, Per Aage Lysaa, and Mark Skapinker, and appointed one new director, being Douglas Janzen.

"I have made 3 separate investments into Elevate and believe it will become a very important player in the ‎vertical farming industry. I think the company has huge potential and is an attractive opportunity for ESG ‎investors." says Douglas Janzen, Director of Elevate Farms.

Mr. Janzen has over 20 years of experience in banking investments and managing growth companies with a particular focus on life sciences and biotech. It is expected that Mr. Janzen's involvement will help fuel Elevate's growth in the coming years.

Source : Newswire.ca

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.